Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil

Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in... Systemic lupus erythematosus (SLE) treatments progress over the years. However, the mortality remains higher than in the general population. Few studies have examined SLE patients’ survival in Brazil. This study aims to identify the main characteristics and risk factors to predict mortality and recognize the main causes of death in Brazilian patients with SLE. We retrospectively assessed clinical, demographic, and serological characteristics from 600 patients followed since 2001 in SLE outpatient clinic from Hospital de Clínicas de Porto Alegre. Risk factors for mortality were examined by univariate and multivariate Cox proportional hazards regression analyses. A p < 0.05 was considered significant. There were 527 survivors (87.83%). The main causes of death were cardiovascular disease (17%), infection (17%), and infection and SLE activity (17%). Risk factors for death were age at diagnosis (HR 1.065, CI 95% 1.039–10.092), SLICC damage index (HR 1.299, CI 95% 1.076–1569), antiphospholip syndrome (HR 3.021, CI 95% 1.307–6.985), and metilprednisolone pulse (HR 2.628, CI 95% 1.283–5.383). Antimalarials was a protective factor for death (HR 0.191, CI 95% 0.064–0.570). Cardiovascular disease, infection, and SLE activity associated with infection were the main known causes of deaths in our SLE patients. Secondary antiphospolipid syndrome, highest score in SLICC damage index, advanced age at diagnosis, and high dose of corticosteroids were risk factors for mortality. Antimalarials was an important protective factor. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Rheumatology Springer Journals

Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil

Loading next page...
 
/lp/springer_journal/survival-analysis-of-patients-with-systemic-lupus-erythematosus-in-a-3Ew92bvw1a

References (31)

Publisher
Springer Journals
Copyright
Copyright © 2017 by International League of Associations for Rheumatology (ILAR)
Subject
Medicine & Public Health; Rheumatology
ISSN
0770-3198
eISSN
1434-9949
DOI
10.1007/s10067-017-3735-1
pmid
28653264
Publisher site
See Article on Publisher Site

Abstract

Systemic lupus erythematosus (SLE) treatments progress over the years. However, the mortality remains higher than in the general population. Few studies have examined SLE patients’ survival in Brazil. This study aims to identify the main characteristics and risk factors to predict mortality and recognize the main causes of death in Brazilian patients with SLE. We retrospectively assessed clinical, demographic, and serological characteristics from 600 patients followed since 2001 in SLE outpatient clinic from Hospital de Clínicas de Porto Alegre. Risk factors for mortality were examined by univariate and multivariate Cox proportional hazards regression analyses. A p < 0.05 was considered significant. There were 527 survivors (87.83%). The main causes of death were cardiovascular disease (17%), infection (17%), and infection and SLE activity (17%). Risk factors for death were age at diagnosis (HR 1.065, CI 95% 1.039–10.092), SLICC damage index (HR 1.299, CI 95% 1.076–1569), antiphospholip syndrome (HR 3.021, CI 95% 1.307–6.985), and metilprednisolone pulse (HR 2.628, CI 95% 1.283–5.383). Antimalarials was a protective factor for death (HR 0.191, CI 95% 0.064–0.570). Cardiovascular disease, infection, and SLE activity associated with infection were the main known causes of deaths in our SLE patients. Secondary antiphospolipid syndrome, highest score in SLICC damage index, advanced age at diagnosis, and high dose of corticosteroids were risk factors for mortality. Antimalarials was an important protective factor.

Journal

Clinical RheumatologySpringer Journals

Published: Jun 26, 2017

There are no references for this article.